echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA approves Brexafemme, the first new class of antifungal drug, Hausen owns Chinese rights

    FDA approves Brexafemme, the first new class of antifungal drug, Hausen owns Chinese rights

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Synexis, a partner of Hausen Pharmaceuticals, announced that the US Food and Drug Administration has approved a new broad-spectrum antifungal drug Brexafemme, which is an oral drug for the treatment of female patients with vulvovaginal candidiasis


    Vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection caused by Candida, is the second most common cause of vaginitis


    At present, the treatment of VVC includes several topical azole antifungals (clotrimazole, miconazole, etc.


    It is reported that on February 17 this year, Hausen Pharmaceuticals and Scinexis signed a strategic cooperation agreement to obtain ibrexafungerp's exclusive rights in the development and commercialization of ibrexafungerp in Greater China (including Hong Kong, Macau and Taiwan).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.